Abstract

  One of the most common sites of gastrointestinal neuroendocrine tumour is the pancreas. They are known as Pancreatic neuroendocrine tumour (PNET). The previous incidence rate of 0.43/100,000 has more than doubled in last few decades. Most of the PNETs are clinically silent and show slight male preponderance. 10% of PNETs are functional, associated with genetic syndromes and represent as cystic lesion on radiology. Proper pre-operative work up including endocrine testing, tumour marker study and imaging is necessary to establish the diagnosis. Since they have malignant potential, surgery is the treatment of choice for resectable tumours among the various treatment modalities available. We are presenting a case of 50 years old lady having multiple soft tissue lesions involving distal CBD, head, body and tail of pancreas. She underwent spleen preserving total pancreatectomy with Roux-en-Y hepaticojejunostomy and gastrojejunostomy. Post-operative recovery was uneventful and glycaemic control was achieved with pharmacotherapy. We will discuss the various aspects of PNETs in this report.

Keywords: Pancreatic Neuroendocrine Tumour; Pancreas; Spleen Preserving; Total Pancreatectomy

References

1. Halfdanarson TR., et al. “Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival”. Annuals of Oncology 19 (2008): 1727-1733.
2. Lawrence B., et al. “The epidemiology of gastroenteropancreatic neuroendocrine tumors”. Endocrinology and Metabolism Clinics of North America 40 (2011): 1-18.
3. Halfdanarson TR., et al. “Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors”. Endocrine-Related Cancer 15 (2008): 409-427.
4. Fraenkel M., et al. “Epidemiology of gastroenteropancreatic neuroendocrine tumours”. Best Practice and Research: Clinical Gastroenterology 26 (2012): 691-703.
5. Triponez F., et al. “Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas”. Annals of Surgery 243 (2006): 265-72.
6. Perren A., et al. “Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas”. The Journal of Clinical Endocrinology and Metabolism 92 (2007): 1118-1128.
7. Jensen RT., et al. “Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies”. Cancer 113 (2008): 1807-1843.
8. Pipeleers-Marichal M., et al. “Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome”. The New England Journal of Medicine 322 (1990): 723-727.
9. Dean PG., et al. “Are patients with multiple endocrine neoplasia type I prone to premature death?”. World Journal of Surgery 24 (2000): 1437-1441.
10. de Wilde RF., et al. “Well differentiated pancreatic neuroendocrine tumors: from genetics to therapy”. Nature Reviews Gastroenterology and Hepatology 9 (2012): 199-208.
11. Vortmeyer AO., et al. “Nonislet origin of pancreatic islet cell tumors”. The Journal of Clinical Endocrinology and Metabolism 89 (2004): 1934-1938.
12. Jiao Y., et al. “DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors”. Science 331 (2011): 1199-1203.
13. Klimsta DS., et al. “Neuroendocrine neoplasms of the pancreas”. In: Bosman F, Carneiro F, Hruban RH., et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press (2010): 322-326.
14. Rindi G., et al. “TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system”. Virchows Archives 449 (2006): 395-401.
15. Exocrine and Endocrine Pancreas. AJCC Cancer Staging Manual. New York, NY: Springer (2010): 241-249.
16. Paik WH., et al. “Clinical usefulness of plasma chromogranin A in pancreatic neuroendocrine neoplasm”. Journal of Korean Medical Science 28 (2013): 750-754.
17. Singh S and Law C. “Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors”. Expert Review of Gastroenterology and Hepatology 6 (2012): 313-334.
18. Vinik AI., et al. “Biochemical testing for neuroendocrine tumors”. Pancreas 38 (2009): 876-889.
19. Oberg K. “Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours”. Endocrine Relation Cancer 18 (2011): S17-25.
20. Anders S. “Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumors”. Best Practice and Research: Clinical Gastroenterology 26 (2012): 803-818.
21. Herwick S., et al. “MRI of islet cell tumors of the pancreas”. AJR American Journal of Roentgenology 187 (2006): W472-480.
22. Sundin A., et al. “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations”. Neuroendocrinology 90 (2009): 167-183.
23. Oberg K. “Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors”. Clinics (Sao. Paulo) 67 (2012): 109-112.
24. Joseph S., et al. “Neuroendocrine tumors: current recommendations for diagnosis and surgical management”. Endocrinology and Metabolism Clinics of North America 40 (2011): 205-31.
25. de Herder WW., et al. “Neuroendocrine tumors and somatostatin: imaging techniques”. Journal of Endocrinology Investigation 28 (2005): 132-136.
26. Garin E., et al. “Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors”. The Journal of Nuclear Medicine 50 (2009): 858-864.
27. Binderup T., et al. “18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors”. Clinical Cancer Research 16 (2010): 978-985.
28. Frilling A., et al. “Multimodal management of neuroendocrine liver metastases”. HPB (Oxford) 12 (2010): 361-379.
29. Kim MK. “Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors”. Gut Liver 6 (2012): 405-410.
30. Atiq M., et al. “EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience”. Digestive Diseases and Sciences 57 (2012): 791-800.
31. Lennon AM., et al. “EUS-guided tattooing before laparoscopic distal pancreatic resection (with video)”. Gastrointestinal Endoscopy 72 (2010): 1089-1094.
32. Minkowski O. “De l’exirpation des pancéas chez les animoux et du diabète experimental”. Semaine Med (Paris) 9 (1889): 175-176.
33. Rockey EW. “Total pancreatectomy for carcinoma: case report”. Annals of Surgery 118 (1943): 603-611.
34. Priestley JT., et al. “Total pancreatectomy for hyperinsulinism due to an islet-cell adenoma: survival and cure at sixteen months after operation presentation of metabolic studies”. Annals of Surgery 119 (1944): 211-221.
35. Müller MW., et al. “Is there still a role for total pancreatectomy?”. Annals of Surgery 246 (2007): 966-974 discussion 974-975.
36. Epelboym I., et al. “Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection”. Journal of Surgery and Research 187 (2014): 189-196.
37. Domínguez-Muñoz JE. “Pancreatic enzyme therapy for pancreatic exocrine insufficiency”. Current Gastroenterology Report 9 (2007): 116-122.
38. Barbier L., et al. “Impact of total pancreatectomy: short- and long-term assessment”. HPB (Oxford) 15 (2013): 882-892.
39. Unger RH. “Glucagon physiology and pathophysiology”. The New England Journal of Medicine 285 (1971): 443-449.
40. Slezak LA and Andersen DK. “Pancreatic resection: effects on glucose metabolism”. World Journal of Surgery 25 (2001): 452-460.

Citation

Citation: Shubhayu Banerjee., et al. “Spleen Preserving Total Pancreatectomy in a Case of Multiple Pancreatic Neuroendocrine Tumour". Acta Scientific Gastrointestinal Disorders 3.11 (2020): 48-55.

Copyright

Copyright: © 2020 Shubhayu Banerjee., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.